Matthew K Fust has sold stock and made no open-market buys since May 2018

Matthew K. Fust is a corporate finance executive and board director in the biopharmaceutical sector, currently serving as a director of Neumora Therapeutics, Inc. (NASDAQ: NMRA) and trading as a corporate insider in that capacity.( An experienced life sciences finance leader, he has more than two decades of service as chief financial officer for biopharmaceutical companies, including Onyx Pharmaceuticals, Jazz Pharmaceuticals, Perlegen Sciences, and ALZA Corporation, where he helped private and public firms raise capital through partner financings, initial public offerings, and mergers and acquisitions.( In addition to Neumora, he serves or has served on the boards of Atara Biotherapeutics, Crinetics Pharmaceuticals, Ultragenyx Pharmaceutical, ArsenalBio, Dermira, MacroGenics, and other life science companies, and acts as an independent advisor to private and publicly traded life sciences companies.(

Fust’s career began in consulting in Andersen Consulting’s healthcare strategy practice before he moved into senior operating roles in industry.( He holds a BA in Accounting from the University of Minnesota Duluth and an MBA from the Stanford University Graduate School of Business, providing the technical and strategic foundation for his long-standing leadership in biopharmaceutical finance and corporate governance.(

Written by Perplexity from public sources.